AMP
LIVE

Serial Number

98377989

Owner

JAGUAR GENE THERAPY, LLC

Attorney

J. Dickson Phillips III

First Use Date

Jan 16, 2024

Filing Date

Jan 26, 2024

Add to watchlist:

No watchlists yet
View on USPTO

AMP Trademark

Serial Number: 98377989 • Registration: 7896266

AMP is a trademark filed by JAGUAR GENE THERAPY, LLC on January 26, 2024. The trademark is classified under Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

JAGUAR GENE THERAPY, LLC (10 trademarks)

TWO CONWAY PARK, SUITE 300
LAKE FOREST, IL 60045

Entity Type: 16

Advanced Medicine Partners, LLC (4 trademarks)

2 Conway Park, 150 N. Field Dr. Ste 300
Lake Forest, IL 60045

Entity Type: 16

Trademark Details

Filing Date

January 26, 2024

Registration Date

August 19, 2025

First Use Anywhere

January 16, 2024

First Use in Commerce

January 16, 2024

Published for Opposition

March 18, 2025

Goods & Services

Biomanufacturing for others, namely, manufacturing of pharmaceuticals using biological organism in the manufacturing process; custom manufacture for others of products relating to biotechnology, namely, recombinant proteins for use in the biotechnology industries; custom manufacture for others of cell therapy products; custom manufacture for others of gene therapy products; custom manufacture of pharmaceuticals in accordance with specific standards GMP regulations

Contract development and manufacturing organization (CDMO) services, namely, pharmaceutical drug development services; consulting and advisory services in the field of analytical development and quality control testing of pharmaceutical, gene therapy, and cell therapy products; consulting and advisory services in the field of manufacturing process development for pharmaceutical, gene therapy and cell therapy products; consulting in the field of chemistry manufacturing and controls (CMC) activities; testing of pharmaceutical, gene therapy, and cell therapy products and materials; quality control testing of pharmaceutical products and materials, namely, biopharmaceutical products and materials in accordance with specifications or requirements of regulatory standards applicable in target countries; testing and validation services of biopharmaceutical products to assure compliance with global regulatory requirements, specifications, and industry standards for pharmaceutical, cell therapy and gene therapy methods of development; technical consulting for regulatory compliance in the field of chemistry manufacturing and controls (CMC)

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Aug 19, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Aug 19, 2025 R.PR
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Jul 27, 2025 ETOP
EXTENSION OF TIME TO OPPOSE RECEIVED
Apr 17, 2025 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 18, 2025 NPUB
PUBLISHED FOR OPPOSITION
Mar 18, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 12, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 21, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 20, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 19, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 19, 2025 TROA
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Feb 5, 2025 ASGN
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Nov 15, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Nov 15, 2024 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 20, 2024 GNRN
NON-FINAL ACTION E-MAILED
Aug 20, 2024 GNRT
NON-FINAL ACTION WRITTEN
Aug 20, 2024 CNRT
ASSIGNED TO EXAMINER
Aug 12, 2024 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
May 7, 2024 MDSM
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 6, 2024 NWOS
NEW APPLICATION ENTERED
Jan 30, 2024 NWAP